From the 26th to the 29th of June, the CLINAM (Clinical Nanomedicine and Targeted Medicine) Conference is taking place in Basel, Switzerland. The theme of this year’s edition is Enabling Technologies for Personalized Medicine. This event gathers various large European actors in the field of biotechnologies, medicine, and nanomedicine including the European Commission, nanomedicine, nanotox, EMRS, EMPA, and much more.
In the previous eight years, the CLINAM Summit grew to the largest in its field with 12 presenting Noble Laureates and more than 500 participants from academia, industry, regulatory authorities and policy from over 40 countries in Europe and worldwide. With this success and broad support by well 31 renowned collaborating initiatives, the CLINAM‐Summit is today a most important marketplace for scientific exchange and discussions of clinical, regulatory, political and ethical aspects in this field of cutting‐edge medicine.
The CLINAM Summit emerged as exquisite forum for translation from bench to bedside for European and international networking, for industrial collaboration between companies, with academia, and as point‐of‐contact with customers. The summit is presently the only place to meet every year the regulatory authorities from all continents to debate the needs of all stakeholders in the field. CLINAM 9/2016 continues with its tradition to cover the manifold interdisciplinary fields of Clinical and Targeted Nanomedicine in major and neglected diseases. As special focus area, CLINAM 09/2016 adds translation and enabling technologies, including, cutting‐edge molecular profiling, nano‐scale analytics, single cell analysis, stem cell technologies, tissue engineering, in and ex vivo systems as well as in vitro substitute systems for efficacy and toxicity testing.
CLINAM 09/2016 covers the spectrum of Nanomedicine and Targeted Medicine from new materials and enabling technologies over diagnostic and therapeutic translation to clinical applications in infectious, inflammatory and neurodegenerative diseases, cancer and regenerative medicine to societal implications, strategical issues, and regulatory affairs. The Summit is divided into four tracks in parallel and provides ample possibilities for exhibitors to make decision maker contacts. The Nobel Laureate Prof. Stefan Hell will open the Summit. Participants are invited to bring samples to test the Stimulated Emission Depletion (STED) Microscopy within the exhibition. Live Testing the STED Microscope The presence of a STED Microscope will give for participants of CLINAM the possibility to bring samples and to investigate the revolutionary visibility. All participants get a link for label protocols before the Summit which gives information how to prepare the samples. STED Microscopes are currently in the market by the companies Abberior and Leica. The initiative to enable people to investigate comes from CLINAM in cooperation with Beckman Coulter, Leica and Abberior.